Business Wire

MI-LINEAGE-LOGISTICS

10.9.2020 09:02:14 CEST | Business Wire | Press release

Share
Lineage Logistics Significantly Expands Cold Storage Warehouse Capacity in the United Kingdom

Lineage Logistics, LLC (“Lineage” or the “Company”), the world’s largest and most innovative provider of temperature-controlled logistics solutions, today announced significant expansion plans in the United Kingdom at its Peterborough Superhub in the South East just 70 miles from Central London and at its Northern Superhub in Heywood near Manchester.

Lineage broke ground on a 92,000-pallet-position, fully automated expansion at its Peterborough location to form a strategically positioned South Eastern Superhub, which will serve both retail and foodservice customers with unique supply chain requirements. This 35-metre tall expansion will feature some of the world’s most sophisticated automation and refrigeration technology, helping to reduce energy consumption and overall environmental impact. This new capacity will complement 26,000 existing conventional pallet positions at the property, which combined with the expansion’s automated design will enable maximum flexibility and as highly customized solutions for customers. This significant investment brings Lineage’s total automated warehouse count in the UK to six, with a total of 330,000 automated pallet positions.

“Lineage’s South Eastern Superhub is extremely well situated and in close proximity to major motorways that are key to the UK’s supply chain, strengthening our ability to efficiently connect customers with major food markets and population centers,” said Mike McClendon, Lineage’s President of International Operations & EVP of Network Optimization. “We are also thrilled to offer a combination of automation and conventional racking upon completion, which will allow us to meet the diverse needs of both retail and foodservice sectors while also delivering energy efficient and cost-effective solutions for customers.”

Lineage’s phased expansion approach in Peterborough is in response to growing customer demand from both online and conventional grocery sales – a trend which was accelerated as a result of the COVID-19 pandemic. In the UK, online sales now account for 13% of all grocery sales, up from 7.4% in March 2020, and new online customers are predicted to continue shopping online (Kantar). Frozen items have also increased in popularity, and the sector is up 22% year over year.

In addition to Lineage’s expansion in Peterborough, the final phase of the Company’s expansion plans in Heywood will be fully operational in March 2021 and add 22,000 pallet positions to the existing location.

“Our large expansions in these two critical logistics hubs highlight Lineage’s commitment to adapting to our customers’ demands as consumer expectations shift in the UK and around the globe,” said Greg Lehmkuhl, President and Chief Executive Officer of Lineage. “We are, and have always been, 100% focused on our customers and their extended supply chains, and we are pleased to make these significant investments, create more than 230 much-needed jobs and provide expanded access to our next-generation cold storage network.”

Lineage Logistics is the largest temperature-controlled supply chain and logistics provider in the UK, and will offer over 525,000 pallet positions of capacity in country following construction. The company supports over 2,000 regional, national and international customers across 14 facilities nationwide, including Scotland, and complements its warehouses with one of the UK’s largest and most reliable transportation networks. Over 1,500 of Lineage’s 16,000 global employees are based in the UK.

Lineage’s cold storage campuses in the UK complement the Company’s international network of facilities and provides an opportunity to reduce unnecessary miles travelled by food through its location and capacity. These expansions follow Lineage’s recent entrance into the Nordic and Canadian markets and increase overall capacity to 1.9 billion cubic feet and 56 million square feet of capacity across more than 320 facilities in 13 countries, spanning North America, South America, Europe, Asia, Australia and New Zealand.

About Lineage Logistics

Lineage is the world’s largest and most innovative provider of temperature-controlled logistics solutions. Lineage’s expertise in end-to-end logistical solutions, its unrivaled real estate network, and its use of technology combine to promote food safety, increase distribution efficiency, advance sustainability, lessen environmental impact, and minimize supply chain waste. As a result, Lineage helps customers ranging from Fortune 500 companies to small family-owned businesses increase the efficiency and protect the integrity of their temperature-controlled supply chain. In recognition of the company’s leading innovations, Lineage was recognized as the No 1. Data Science company on Fast Company’s Annual list of The World’s Most Innovative Companies in 2019, in addition to ranking 23rd overall in an evaluation of thousands of companies worldwide. (www.lineagelogistics.com )

Link:

ClickThru

Social Media:

https://www.facebook.com/lineagelogistics/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye